on Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics to Announce New Oral Obesity Candidate
Protagonist Therapeutics, Inc. will host a webcast and conference call to reveal a new oral obesity development candidate. The event is scheduled for Monday, June 30th, at 4:30 pm ET. Participants can join via the provided US and international dial-in numbers or through a webcast link.
The company plans to share in vitro and pre-clinical proof-of-concept study results during the session. Protagonist continues to advance its biopharmaceutical pipeline, with notable developments including icotrokinra and rusfertide, both currently in advanced clinical phases.
A replay of the conference will be available on Protagonist's Investor Relations webpage post-event. This announcement underscores the company's ongoing commitment to addressing clinically and commercially validated targets through innovative oral drug discovery programs.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Protagonist Therapeutics, Inc. news